COSCIENS Biopharma CSCI.TO · CAD

Its shares trade on Toronto Stock Exchange under the ticker CSCI.TO. It has been listed since 19 December 1995. In the fiscal year to 31 December 2025, it reported revenue of $7.5m and a net loss of $10.4m. At that date it held total assets of $21.4m and shareholders' equity of $3.8m.

Æterna Zentaris, Inc. operates as a specialty biopharmaceutical company commercializing and developing therapeutics and diagnostic tests. The company is headquartered in Summerville, South Carolina. The firm operates through the biopharmaceutical segment. The firm is engaged in drug development activities and in the promotion of products for others. The firm's principal product candidates are Zoptrex (zoptarelin doxorubicin) and Macrilen (macimorelin) in oncology and endocrinology. The firm focuses on its product candidates Zoptrex and Macrilen, which are in Phase III clinical development, and on a luteinizing hormone-releasing hormone (LHRH)-disorazol Z conjugate (AEZS-138), which is in pre-clinical development in oncology and is available for partnering. The firm's direct and indirect subsidiaries include AEZS GmbH, Zentaris IVF GmbH and Aeterna Zentaris, Inc.

Figures and description from our data supplier, not checked against the company's own report.

• Mr. Peter PuccettiChairman of the Board, Interim Chief Executive Officer, since 2025
• Mr. Giuliano La FrattaChief Financial Officer, Senior Vice President, since 2022$176,984
• Mr. Michel RegnierSenior Vice President, Chief Technology Officer$213,977
• Dr. Matthias GerlachSenior Vice President - Manufacturing and Supply Chain, Managing Director - AEZS Germany$138,368
• Ms. Nicola AmmerSenior Vice President - Clinical Development, Chief Medical Officer$197,329
• Mr. Anthony GiovinazzoDirector
• Dr. Ulrich KosciessaDirector$187,895
• Mr. Ronald MillerDirector, since 2024$240,334
• Mr. Robert SeagerDirector
• Mr. David SpearDirector

Overall

0

Environment

0

Social

0

Governance

0

Data on this tab

Our data supplier

Chart on the Overview

TradingView

Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.